Scientists have identified a new type of brain plaque, offering fresh insights into Alzheimer’s disease. Researchers at the University of Minnesota have discovered what they term “mitochondrial plaques.” This finding has the potential to shift current understanding of Alzheimer’s development and open avenues for new treatments.
The study, published in Nature Neuroscience, indicates that mitochondrial plaques may emerge before the well-known beta-amyloid plaques. Traditionally, beta-amyloid plaques and neurofibrillary tangles have been the primary focus of Alzheimer’s research.
Alzheimer’s leads to the gradual loss of brain cells and cognitive abilities. The newly identified plaques, formed independently of traditional amyloid plaques, might appear at the earliest stages of the disease. Moreover, these plaques contain high levels of amyloid precursor protein, which is critical for beta-amyloid formation.
“This discovery identifies mitochondrial plaques as a previously unrecognized feature of Alzheimer’s disease,” stated Paul Robbins, a professor at the University of Minnesota Medical School.
Robbins suggested the potential for new strategies to slow or prevent Alzheimer’s by studying these plaques further. Unlike traditional plaques found outside brain cells, mitochondrial plaques directly affect neurons, making them a potential target for treatment.
The discovery raises the possibility that Alzheimer’s progression could begin earlier and through different biological pathways. However, more research is necessary to fully comprehend these findings.
Laura Bojarskaite, a neuroscientist from the University of Oslo, emphasized that if confirmed, these results could transform scientists’ understanding of Alzheimer’s onset. She highlighted the shift from focusing on extracellular processes to those happening inside neurons.
Bojarskaite discussed the ongoing question about mitochondrial dysfunction’s role in Alzheimer’s. Scientists are unsure if such dysfunctions trigger the disease or result from other ongoing changes.
Understanding why some neurons are more vulnerable and whether mitochondrial changes are common across patients remains a research focus. If future studies confirm mitochondrial plaques form before amyloid plaques, they could serve as early biomarkers, allowing for timely interventions.
Bojarskaite acknowledged that numerous challenges lie ahead. Replicating results, observing them in living patients, and linking them to disease progression are essential steps before clinical applications. She urged caution in interpreting these promising findings.
The University of Minnesota team aims to identify biomarkers related to mitochondrial plaques and screen drugs to prevent their accumulation. This work will explore whether these structures directly impact Alzheimer’s disease and if they can be targeted to slow its progression.
Leave a Reply